Skip to content

Study · Non-randomized trial · n = 16 · 1991

9 results

Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure.

Hokken-Koelega AC, Stijnen T, de Muinck Keizer-Schrama SM, Wit JM, Wolff ED, de Jong MC, Donckerwolcke RA, Abbad NC, Bot A, Blum WF

Lancet (London, England)1 Sept 1991Cited by 113 (Europe PMC)

PMID1715501 (opens in a new tab)DOI10.1016/0140-6736(91)90604-n (opens in a new tab)PepBankPUB-01715501
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, GH increased height velocity more than placebo by 2.9 cm per 6 months.

    In plain wordsIn children with chronic renal failure, GH increased growth speed more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight velocity
    Study

    n = 16

    Comparator
    Placebo
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Height-velocity difference
    2.9 cm per 6 months
    GH versus placebo

    Source sentences

    Summary
    Height velocity improved significantly with GH therapy (p less than 0.0001) and placebo (p less than 0.04), but the GH-induced height-velocity increase exceeded that of placebo by 2.9 cm per 6 months.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  2. 02HumanNon-randomized trialOther

    In children with chronic renal failure, prestudy height velocity correlated positively with the height-velocity increase during GH therapy.

    In plain wordsIn children with chronic renal failure, faster growth before treatment was linked to greater growth increases.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreasePrestudy height velocity association
    Study

    n = 16

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    There was a positive relationship between prestudy height velocity and height-velocity increase.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, GH did not affect bone maturation.

    In plain wordsIn children with chronic renal failure, GH did not affect bone maturation.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBone maturation
    Study

    n = 16

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone maturation was not affected.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, GH significantly increased plasma IGF-I.

    In plain wordsIn children with chronic renal failure, GH significantly increased IGF-I.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I
    Study

    n = 16

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    GH caused a significant increase in IGF-I and a moderate increase in IGF-II plasma concentrations.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, GH moderately increased plasma IGF-II.

    In plain wordsIn children with chronic renal failure, GH moderately increased IGF-II.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-II
    Study

    n = 16

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    GH caused a significant increase in IGF-I and a moderate increase in IGF-II plasma concentrations.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, elevated pretreatment IGF-binding protein-1 decreased by almost 50% during GH therapy.

    In plain wordsIn children with chronic renal failure, IGF-binding protein-1 decreased from pretreatment levels during GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseIGF-binding protein-1
    Study

    n = 16

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Decrease
    ≈ 50%
    during GH therapy

    Source sentences

    Summary
    The pretreatment elevation of IGF-binding protein-1 decreased by almost 50% during GH therapy, while IGF-binding protein-3 increased significantly in concentration, although this increase was significantly smaller than the GH-induced increase in IGF-I.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  7. 07HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, GH significantly increased IGF-binding protein-3, but less than IGF-I.

    In plain wordsIn children with chronic renal failure, GH increased IGF-binding protein-3 less than IGF-I.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-binding protein-3
    Study

    n = 16

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    The pretreatment elevation of IGF-binding protein-1 decreased by almost 50% during GH therapy, while IGF-binding protein-3 increased significantly in concentration, although this increase was significantly smaller than the GH-induced increase in IGF-I.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  8. 08HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, fructosamine, lipid, and parathyroid concentrations remained constant during GH therapy.

    In plain wordsIn children with chronic renal failure, fructosamine, lipid, and parathyroid concentrations remained constant during GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeFructosamine, lipid, and parathyroid concentrations
    Study

    n = 16

    Outcome group
    Metabolic pathways and metabolomics · Endocrine and hormones
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Fructosamine, lipid, and parathyroid concentrations remained constant.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.
  9. 09HumanNon-randomized trialEfficacy outcome

    In children with chronic renal failure, renal function deterioration did not accelerate during GH therapy.

    In plain wordsIn children with chronic renal failure, kidney function deterioration did not accelerate during GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeRenal function deterioration
    Study

    n = 16

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    4 IU/m2 per day · subcutaneous · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Renal function deterioration did not accelerate.
    2 context sentences
    Summary · context
    Biosynthetic growth hormone (GH) was given to 20 prepubertal children (eleven boys, nine girls; mean age 9.5 years, range 4-16) with CRF and severe growth retardation in a placebo-controlled, double-blind, cross-over trial. 6 months of subcutaneous injection of GH (4 IU/m2 per day) was either preced…
    Summary · context
    Sixteen children completed the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.